SARS-CoV-2 (COVID-19) Spike Neutralization Single Domain Antibody [1H12]

Contact us
ProSci
Product Code: PSI-SD9857
Product Group: Primary Antibodies
Supplier: ProSci
CodeSizePrice
PSI-SD9857-0.02mg0.02mg£166.00
Quantity:
PSI-SD9857-0.1mg0.1mg£531.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Llama
Antibody Isotype: sdAb
Antibody Clonality: Monoclonal
Antibody Clone: 1H12
Regulatory Status: RUO
Target Species: Virus
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Neutralisation
Shipping:
Dry Ice
Storage:
SARS-CoV-2 (COVID-19) Spike Neutralization Antibody should be stored in working aliquots at -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Images

1 / 2
<strong>Figure 1. ACE2-RBD binding inhibition by Antibody SD9857 (1H12).</strong><br />An ELISA was performed to test whether SARS-CoV-2 (COVID-19) Spike RBD Antibody, SD9857 inhibits the binding of RBD proteins (from the receptor binding domain of the SARS-CoV-2 spike protein wildtype and alpha variant, respectively) to ACE2, a cellular receptor for SARS-CoV-2. The RBD proteins were used as coating antigens at 1 μg/mL. Antibody SD9857 was added at the concentrations indicated followed by the addition of 20 ng/ml human ACE2-Fc. Bound h-ACE2-Fc was detected with a goat anti-human IgG-HRP conjugate (1:20,000 dilution) using the TMB chromogenic substrate system. SD9857 exhibited a dose dependent inhibitory effect on ACE2 binding to RBDs of wild-type and alpha strains.
2 / 2
<strong>Figure 2. Pseudovirus neutralization assay with Antibody SD9857 (1H12).</strong><br />A pseudovirus neutralization assay was performed to test whether SD9857 inhibits the entry of SARS-CoV-2 spike carrying pseudovirus into 293T-hsACE2 cells. The virus-like particles carry a luciferase reporter which can be detected using Promega’s Renilla-Glo Luciferase Assay System. Antibody SD9857 was added to the cells at the concentrations indicated together with the virus-like particles. After 72 hrs incubation infectivity was determined by measuring relative light units (RLU) produced by the introduced luciferase reporter. The RLUs obtained with the no-antibody control were set as 100% infectivity, i.e., 0% inhibition). SD9857 exhibited a dose dependent neutralizing effect on the wild-type SARS-CoV-2 pseudovirus.
❮❯

<strong>Figure 1. ACE2-RBD binding inhibition by Antibody SD9857 (1H12).</strong><br />An ELISA was performed to test whether SARS-CoV-2 (COVID-19) Spike RBD Antibody, SD9857 inhibits the binding of RBD proteins (from the receptor binding domain of the SARS-CoV-2 spike protein wildtype and alpha variant, respectively) to ACE2, a cellular receptor for SARS-CoV-2. The RBD proteins were used as coating antigens at 1 μg/mL. Antibody SD9857 was added at the concentrations indicated followed by the addition of 20 ng/ml human ACE2-Fc. Bound h-ACE2-Fc was detected with a goat anti-human IgG-HRP conjugate (1:20,000 dilution) using the TMB chromogenic substrate system. SD9857 exhibited a dose dependent inhibitory effect on ACE2 binding to RBDs of wild-type and alpha strains.
<strong>Figure 2. Pseudovirus neutralization assay with Antibody SD9857 (1H12).</strong><br />A pseudovirus neutralization assay was performed to test whether SD9857 inhibits the entry of SARS-CoV-2 spike carrying pseudovirus into 293T-hsACE2 cells. The virus-like particles carry a luciferase reporter which can be detected using Promega’s Renilla-Glo Luciferase Assay System. Antibody SD9857 was added to the cells at the concentrations indicated together with the virus-like particles. After 72 hrs incubation infectivity was determined by measuring relative light units (RLU) produced by the introduced luciferase reporter. The RLUs obtained with the no-antibody control were set as 100% infectivity, i.e., 0% inhibition). SD9857 exhibited a dose dependent neutralizing effect on the wild-type SARS-CoV-2 pseudovirus.

Documents

Further Information

Additional Names:
SARS-CoV-2 (COVID-19) Spike S1 Antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Surface Glycoprotein, Spike protein
Background:
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019?20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).
Background References:
  • Gorbalenya. bioRxiv: 2020.
  • Hui et al. Int J Infect Dis. 2020;91:264-266.
  • Belouzard et al. Viruses. 2012;4(6):1011-33.
  • Lee et al. J Virol. 2006;80(8):4079-87.
  • Wan et al. J Virol. 2020.
  • Wrapp et al. Science. 2020.
Buffer:
SARS-CoV-2 (COVID-19) Spike Neutralization Antibody is supplied in PBS.
Concentration:
batch dependent
Conjugate:
Unconjugated
Immunogen:
SARS-CoV-2 S protein RBD containing C-terminal His Tag. The protein was expressed in human 293 cells (HEK293). It contains amino acids Arg 319 - Lys 537.
NCBI Gene ID #:
43740568
NCBI Official Name:
surface glycoprotein
NCBI Official Symbol:
S
NCBI Organism:
SARS-CoV-2
Physical State:
Liquid
Protein Accession #:
QHD43419
Protein GI Number:
1791269090
Purification:
SARS-CoV-2 (COVID-19) Spike Neutralization Antibody is affinity chromatography purified via Nickel column. Antibody is supplied as a His-tagged purified protein.??It also contains a myc-tag for detection.
Research Area:
Infectious Disease,COVID-19
Swissprot #:
P0DTC2
User NOte:
Optimal dilutions for each application to be determined by the researcher.